指南与共识心脑血管急症儿科与产科急症

2021年PACES专家共识声明:儿科患者心血管植入式电子设备的适应证与管理——执行摘要

2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: Executive summary.
指南 / 共识 · Indian Pacing Electrophysiol J · 2021-07-29
一句话结论PACES发布专家共识,针对≤21岁儿科患者更新并细化心血管植入式电子设备(CIED)的适应证、导线系统管理与随访评估。

该文件为2021年PACES专家共识声明的执行摘要,旨在更新和进一步明确儿科患者(定义为≤21岁)心血管植入式电子设备(CIED)的使用与管理适应证。文件指出,2018年ACC/AHA/HRS关于心动过缓与心脏传导延迟的指南推荐针对>18岁患者,而年轻患者CIED适应证不同且存在尺寸相关技术因素,因此需制定儿科专属共识。文件主要聚焦特定疾病/诊断分类下CIED的适应证,同时提供导线系统管理和随访评估的指导。推荐以简化的模块化格式呈现,每个部分包括完整的推荐表格及简要支持文本和精选参考文献。

要点

  • 本共识适用于≤21岁儿科患者CIED的适应证与管理,同时认识到18至21岁患者照护常存在重叠。
  • 2018年ACC/AHA/HRS心动过缓与心脏传导延迟指南的推荐针对>18岁患者,不直接适用于儿科人群。
  • 文件聚焦特定疾病/诊断分类下CIED的适应证,并提供导线系统管理与随访评估的指导。
  • 推荐以模块化格式呈现,每个部分含完整推荐表格及简要支持文本和精选参考文献。
  • 本文件为执行摘要,不提供每条推荐的详尽讨论,完整内容见PACES-CIED综合文件。

适用人群与场景

  • 儿科患者,定义为≤21岁,需评估心血管植入式电子设备(CIED)适应证或已植入CIED需管理。
  • 认识到18至21岁患者照护在儿科与成人体系间常存在重叠。

处置流程与药物剂量

  • 文件提供儿科CIED患者导线系统管理和随访评估的指导。
  • 推荐以模块化格式呈现,每个部分包括完整推荐表格及简要支持文本和精选参考文献。

研究设计与关键结果

  • 本文件为2021年PACES专家共识声明的执行摘要,旨在更新和进一步明确儿科患者(≤21岁)CIED使用与管理的适应证。
  • 文件主要聚焦特定疾病/诊断分类下CIED的适应证,并提供导线系统管理和随访评估的指导。
  • 推荐以简化的模块化格式呈现,每个部分包括完整推荐表格及简要支持文本和精选参考文献。

证据类型、等级与局限

  • 证据类型:专家共识声明(ECS)。
  • 本文件为执行摘要,不提供每条推荐的详尽讨论,完整内容见PACES-CIED综合文件。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文未据此给出推荐。

指南或共识出处

  • 2021 PACES专家共识声明:儿科患者心血管植入式电子设备的适应证与管理——执行摘要(Indian Pacing Electrophysiol J)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Guidelines for the implantation of cardiac implantable electronic devices (CIEDs) have evolved since publication of the initial ACC/AHA pacemaker guidelines in 1984 [1]. CIEDs have evolved to include novel forms of cardiac pacing, the development of implantable cardioverter defibrillators (ICDs) and the introduction of devices for long term monitoring of heart rhythm and other physiologic parameters. In view of the increasing complexity of both devices and patients, practice guidelines, by necessity, have become increasingly specific. In 2018, the ACC/AHA/HRS published Guidelines on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay [2], which were specific recommendations for patients >18 years of age. This age-specific threshold was established in view of the differing indications for CIEDs in young patients as well as size-specific technology factors. Therefore, the following document was developed to update and further delineate indications for the use and management of CIEDs in pediatric patients, defined as ≤21 years of age, with recognition that there is often overlap in the care of patents between 18 and 21 years of age. This document is an abbreviated expert consensus statement (ECS) intended to focus primarily on the indications for CIEDs in the setting of specific disease/diagnostic categories. This document will also provide guidance regarding the management of lead systems and follow-up evaluation for pediatric patients with CIEDs. The recommendations are presented in an abbreviated modular format, with each section including the complete table of recommendations along with a brief synopsis of supportive text and select references to provide some context for the recommendations. This document is not intended to provide an exhaustive discussion of the basis for each of the recommendations, which are further addressed in the comprehensive PACES-CIED document [3], with further data easily accessible in electronic searches or textbooks.

来源:Indian Pacing Electrophysiol J,查看原文。版权归原作者所有。

参考来源

  1. Silka MJ, Shah MJ, Avari Silva JN, et al. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: Executive summary. Indian Pacing Electrophysiol J. 2021. PMID: 34333142. doi:10.1016/j.ipej.2021.07.006

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。